Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Fennec Pharmaceuticals Inc. before investing.

In this article, we go over a few key elements for understanding Fennec Pharmaceuticals Inc.’s stock price such as:

• Fennec Pharmaceuticals Inc.’s current stock price and volume
• Why Fennec Pharmaceuticals Inc.’s stock price changed recently
• Upgrades and downgrades for FENC from analysts
• FENC’s stock price momentum as measured by its relative strength

About Fennec Pharmaceuticals Inc. (FENC)

Before we jump into Fennec Pharmaceuticals Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Want to learn more about Fennec Pharmaceuticals Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Fennec Pharmaceuticals Inc..

Fennec Pharmaceuticals Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Fennec Pharmaceuticals Inc.’s stock price was $9.570.

Fennec Pharmaceuticals Inc. is down 3.43% from its previous closing price of $9.910.

During the last market session, Fennec Pharmaceuticals Inc.’s stock traded between $9.396 and $10.070. Currently, there are approximately 34.34 million shares outstanding for Fennec Pharmaceuticals Inc..

Fennec Pharmaceuticals Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Fennec Pharmaceuticals Inc. Stock Price History

Fennec Pharmaceuticals Inc.’s (FENC) price is currently down 10.98% so far this month.

During the month of July, Fennec Pharmaceuticals Inc.’s stock price has reached a high of $11.240 and a low of $9.396.

Over the last year, Fennec Pharmaceuticals Inc. has hit prices as high as $11.310 and as low as $5.650. Year to date, Fennec Pharmaceuticals Inc.’s stock is up 24.29%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Fennec Pharmaceuticals Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there were 0 analysts who downgraded Fennec Pharmaceuticals Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Fennec Pharmaceuticals Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Fennec Pharmaceuticals Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Fennec Pharmaceuticals Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Fennec Pharmaceuticals Inc. (FENC) by visiting AAII Stock Evaluator.

Relative Price Strength of Fennec Pharmaceuticals Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Fennec Pharmaceuticals Inc. has a weighted four-quarter relative price strength of 9.87%, which translates to a Momentum Score of 82 and is considered to be Very Strong.

Want to learn more about how Fennec Pharmaceuticals Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Fennec Pharmaceuticals Inc. Stock Price: Bottom Line

As of July 31, 2026, Fennec Pharmaceuticals Inc.’s stock price is $9.570, which is down 3.43% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Fennec Pharmaceuticals Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.